HER2/neu, Topoisomerase 2a, Estrogen and Progesterone Receptors: Discordance between Primary Breast Cancer and Metastatic Axillary Lymph Node in Expression and Amplification Characteristics

被引：15
作者：
Ataseven, Beyhan [1 ]
Gologan, Daniela [1 ]
Gunesch, Angela [1 ]
Kehl, Victoria [2 ]
Hoegel, Bernhard [3 ]
Beer, Michaela [3 ]
Eiermann, Wolfgang [1 ]
机构：
[1] Rotkreuzklinikum Frauenklin Munchen, Munich, Germany
[2] Tech Univ Munich, Inst Med Stat & Epidemiol, D-80637 Munich, Germany
[3] Pathol Munchen, Munich, Germany
来源：
BREAST CARE | 2012年 / 7卷 / 06期
关键词：
Breast Cancer; Metastasis; Hormone receptor; HER2/neu; Topoisonnerase; 2a; HER-2; STATUS; IMPACT; DOXORUBICIN; CARCINOMA; SITES; SCORE;
D O I：
10.1159/000345467
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Molecular classification of breast cancer (BC) and the evaluation of new biological markers such as estrogen receptor (ER), progesterone receptor (PR), ErbB2 (HER2) and topoisomerase 2a (Topo2a) status are claimed to be important parameters in the management of BC therapy. In case of heterogeneity between primary BC and metastatic site, this implies profound limitations of efficient systemic therapy. Therefore, it is essential to analyze whether biological markers of BC relate to identical expression profiles of metastatic lymph nodes (mLNs). We used paraffin-embedded tumor tissue from 119 patients with at least 1 mLN. Immunohistochemistry (INC) was used to analyze ER, PR, HER2 and Topo2a. In addition, HER2 and Topo2a amplification was evaluated by fluorescence/chromogenic in situ hybridization (FISH/CISH) in all samples with a HER2 score of 2+/3+ by IHC. Overall, the percentage of discordant marker status in the BC and its mLN was 2.6% for ER, 3.5% for PR, 3.4% for HER2, and 3.4% for Topo2a. With FISH/CISH, the amplification rate for Topo2a and HER2 was concordant in all cases. Because there are no prospective studies, it remains unclear whether these discrepancies have an effect on patient survival.
引用
收藏
页码：465 / 470
页数：6
相关论文
共 30 条
[1]  
Abe O, 2005, LANCET, V366, P2087, DOI 10.1016/s0140-6736(05)66544-0
[2]  
Broom RJ, 2009, ANTICANCER RES, V29, P1557
[3]   Occult axillary lymph node Metastases in breast cancer do matter results of 10-year survival analysis [J].
Cummings, MC ;
Walsh, MD ;
Hohn, BG ;
Bennett, IC ;
Wright, RG ;
McGuckin, MA .
AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2002, 26 (10) :1286-1295
[4]   c-erbB2 expression predicts tamoxifen efficacy in breast cancer patients [J].
De Placido, S ;
Carlomagno, C ;
De Laurentiis, M ;
Bianco, AR .
BREAST CANCER RESEARCH AND TREATMENT, 1998, 52 (1-3) :55-64
[5]  
Depowski PL, 2000, MODERN PATHOL, V13, P524
[6]   Comparison of HER-2 status between primary breast cancer and corresponding distant metastatic sites [J].
Gancberg, D ;
Di Leo, A ;
Cardoso, F ;
Rouas, G ;
Pedrocchi, M ;
Paesmans, M ;
Verhest, A ;
Bernard-Marty, C ;
Piccart, MJ ;
Larsimont, D .
ANNALS OF ONCOLOGY, 2002, 13 (07) :1036-1043
[7]   HER2 status and efficacy of adjuvant anthracyclines in early breast cancer:: A pooled analysis of randomized trials [J].
Gennari, Alessandra ;
Sormani, Maria Pia ;
Pronzato, Paolo ;
Puntoni, Matteo ;
Colozza, Mariantonietta ;
Pfeffer, Ulrich ;
Bruzzi, Paolo .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2008, 100 (01) :14-20
[8]   Comparison of HER-2 status determined by fluorescence in situ hybridization in primary and metastatic breast carcinoma [J].
Gong, Y ;
Booser, DJ ;
Sneige, N .
CANCER, 2005, 103 (09) :1763-1769
[9]   Comparison of HER-2 and hormone receptor expression in primary breast cancers and asynchronous paired metastases: Impact on patient management [J].
Guarneri, Valentina ;
Giovannelli, Simona ;
Ficarra, Guido ;
Bettelli, Stefania ;
Maiorana, Antonino ;
Piacentini, Federico ;
Barbieri, Elena ;
Dieci, Maria Vittoria ;
D'Amico, Roberto ;
Jovic, Gordana ;
Conte, PierFranco .
ONCOLOGIST, 2008, 13 (08) :838-844
[10]  
Hammond MEH, 2010, ARCH PATHOL LAB MED, V134, pE48, DOI 10.1043/1543-2165-134.7.e48
123